628 related articles for article (PubMed ID: 26691333)
21. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.
Germino FW; Neutel JM; Dubiel R; Maa JF; Chavanu KJ
Am J Cardiovasc Drugs; 2012 Oct; 12(5):325-33. PubMed ID: 22920048
[TBL] [Abstract][Full Text] [Related]
22. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
Lacourcière Y; Taddei S; Konis G; Fang H; Severin T; Zhang J
J Hypertens; 2012 Oct; 30(10):2047-55. PubMed ID: 22828090
[TBL] [Abstract][Full Text] [Related]
23. Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan.
Khan W; Moin N; Iktidar S; Sakrani J; Abid R; Afzal J; Maheshwary N; Kumar K; Siddiqi A; Qadir M
Ther Adv Cardiovasc Dis; 2014 Apr; 8(2):45-55. PubMed ID: 24562476
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy.
Weir MR; Shojaee A; Maa JF
Postgrad Med; 2013 Mar; 125(2):124-34. PubMed ID: 23816778
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160 mg monotherapy.
Ahn Y; Kim Y; Chang K; Kim W; Rhee MY; Cha KS; Hyon MS; Shim CY; Lee SY; Kim DI; Kim SW; Lim SW; Han KR; Jo SH; Lee NH; Kwan J; Ahn T
Medicine (Baltimore); 2018 Sep; 97(37):e12329. PubMed ID: 30212981
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy.
Zhu JR; Zhang SY; Gao PJ
Arch Pharm Res; 2014 Dec; 37(12):1588-98. PubMed ID: 25060946
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
Nesbitt SD; Shojaee A; Maa JF; Weir MR
J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
[TBL] [Abstract][Full Text] [Related]
28. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.
Deeks ED
Drugs; 2011 Jan; 71(2):209-20. PubMed ID: 21275446
[TBL] [Abstract][Full Text] [Related]
29. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension.
Volpe M; de la Sierra A; Ammentorp B; Laeis P
Adv Ther; 2014 May; 31(5):561-74. PubMed ID: 24760656
[TBL] [Abstract][Full Text] [Related]
30. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
Weir MR; Hsueh WA; Nesbitt SD; Littlejohn TJ; Graff A; Shojaee A; Waverczak WF; Qian C; Jones CJ; Neutel JM
J Clin Hypertens (Greenwich); 2011 Jun; 13(6):404-12. PubMed ID: 21649839
[TBL] [Abstract][Full Text] [Related]
31. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
Calhoun DA; Lacourcière Y; Chiang YT; Glazer RD
Hypertension; 2009 Jul; 54(1):32-9. PubMed ID: 19470877
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study.
Sung KC; Oh YS; Cha DH; Hong SJ; Won KH; Yoo KD; Rha SW; Ahn YK; Ahn JC; Jang JY; Hong TJ; Cho SK; Park SH; Hyon MS; Nam CW; Chae IH; Yoo BS; Song JM; Jeong JO; Yoon YW; Kim BS; Yang TH; Cho DK; Kim SH; Choi YJ; Ahn JH; Jeon DW; Kim HS
Clin Ther; 2018 Jan; 40(1):50-63.e3. PubMed ID: 29248384
[TBL] [Abstract][Full Text] [Related]
33. Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
Kereiakes DJ; Neutel JM
Drugs R D; 2011 Sep; 11(3):251-7. PubMed ID: 21777013
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.
Volpe M; Miele C; Haag U
Clin Drug Investig; 2009; 29(6):381-91. PubMed ID: 19432498
[TBL] [Abstract][Full Text] [Related]
36. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
Tuomilehto J; Tykarski A; Baumgart P; Reimund B; Le Breton S; Ferber P
Blood Press Suppl; 2008 Jun; 1():15-23. PubMed ID: 18705531
[TBL] [Abstract][Full Text] [Related]
38. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
Destro M; Crikelair N; Yen J; Glazer R
Vasc Health Risk Manag; 2010 Sep; 6():821-7. PubMed ID: 20859551
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
Chrysant SG
Clin Drug Investig; 2010; 30(7):473-82. PubMed ID: 20528002
[TBL] [Abstract][Full Text] [Related]
40. Effects of triple combination therapy with azilsartan/amlodipine/hydrochlorothiazide on office/home blood pressure: a randomized-controlled trial in Japanese essential hypertensive patients.
Rakugi H; Shimizu K; Sano Y; Nishiyama Y; Kinugawa Y; Terashio S
Blood Press Monit; 2018 Apr; 23(2):91-102. PubMed ID: 29239867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
